HadToHavit, Yes, I have seen what appears to be this type of thought process, especially while listening to question and answer periods during quarterly presentations. I would tend to agree with you, especially if the developing party has adverse problems or liability from FDA or trial data directly attributable to their design or a problem they failed to foresee. In this case, a natural reaction to the administration of a new product, even though it could fall into the second category, failed to foresee, is still a natural reaction and certainly not something to try to hide from competitors or constituents. This is the reason for trials in the first place. I would see the inclusion of the Cytosorbent filter as a natural add on for the treatment of an extreme reaction. I see this as a positive fix and support for CAR-T development.
News 
Market Data 
Discover 
